Advances in the diagnosis and treatment of gallbladder carcinoma

Yi LE; Hao YANG; Hu LIU; Zhaoyang CUI; Xiangning ZHAO; Liang AN; Haizhu LI; Shaogeng ZHANG

doi:10.3969/j.issn.1001-5256.2023.11.032

Volume 39 Issue 11

Nov. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(11): 2738-2744

PDF( 868 KB)

Advances in the diagnosis and treatment of gallbladder carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.11.032

Department of Tumor Surgery，Shanghai Mengchao Cancer Hospital，Shanghai 201805，China

Research funding:

Scientific Research Project approved by Health Commission of Jiading District, Shanghai (2022-KY-19)

More Information

Corresponding author: ZHANG Shaogeng， zhangsg302@hotmail.com （ORCID： 0000-0003-0680-2322）
Received Date: 2023-03-14
Accepted Date: 2023-03-22
Published Date: 2023-11-28

Abstract

Abstract

Gallbladder carcinoma is a common malignant tumor of the biliary system characterized by poor specificity of early symptoms， a high degree of malignancy， and rapid progression， and it is difficult to make an early diagnosis. Gallstones and gallbladder polyps are considered the most common risk factors for gallbladder carcinoma. Ultrasound is the preferred examination， while CT， MRI， and PET also have their own advantages. There is a lack of radical treatment methods for gallbladder carcinoma， and surgical operation remains the preferred treatment method for gallbladder carcinoma； however， due to the rapid progression of this disease， most patients have lost the opportunity for surgery at the time of diagnosis. A combination of various treatment modalities， such as radiochemotherapy， targeted therapy， and immunotherapy， has improved the prognosis of patients to a certain extent， but with an unsatisfactory long-term therapeutic effect. Therefore， it is of particular importance to give priority to prevention rather than treatment and emphasize early identification and treatment.
- Gallbladder Neoplasms,
- Risk Factors,
- Diagnosis,
- Therapeutics

FullText(HTML)

References(46)

References

[1]	SHARMA A, SHARMA KL, GUPTA A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update[J]. World J Gastroenterol, 2017, 23( 22): 3978- 3998. DOI: 10.3748/wjg.v23.i22.3978.
[2]	ROA JC, GARCÍA P, KAPOOR VK, et al. Gallbladder cancer[J]. Nat Rev Dis Primers, 2022, 8( 1): 69. DOI: 10.1038/s41572-022-00398-y.
[3]	NAGTEGAAL ID, ODZE RD, KLIMSTRA D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76( 2): 182- 188. DOI: 10.1111/his.13975.
[4]	LI WC, HUANG PZ, LEI PR, et al. Risk factors for the recurrence of stones after endoscopic minimally invasive cholecystolithotomy in China: A meta-analysis[J]. Surg Endosc, 2019, 33( 6): 1802- 1810. DOI: 10.1007/s00464-018-6455-y.
[5]	ZHU Z, LUO K, ZHANG B, WANG G, et al. Risk factor analysis and construction of prediction models of gallbladder carcinoma in patients with gallstones[J]. Front Oncol, 2023, 13: 1037194. DOI: 10.3389/fonc.2023.1037194.
[6]	MCCAIN RS, DIAMOND A, JONES C, et al. Current practices and future prospects for the management of gallbladder polyps: A topical review[J]. World J Gastroenterol, 2018, 24( 26): 2844- 2852. DOI: 10.3748/wjg.v24.i26.2844.
[7]	MISHRA SK, KUMARI N, KRISHNANI N. Molecular pathogenesis of gallbladder cancer: An update[J]. Mutat Res, 2019, 816-818: 111674. DOI: 10.1016/j.mrfmmm.2019.111674.
[8]	MUHAMMAD JS, KHAN MR, GHIAS K. DNA methylation as an epigenetic regulator of gallbladder cancer: An overview[J]. Int J Surg, 2018, 53: 178- 183. DOI: 10.1016/j.ijsu.2018.03.053.
[9]	BRÄGELMANN J, PONCE CB, MARCELAIN K, et al. Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer[J]. Hepatology, 2021, 73( 6): 2293- 2310. DOI: 10.1002/hep.31585.
[10]	LU YY, ZHAO HT, CHENG JM, et al. Consensus for clinical application of molecular diagnosis on hepatobiliary carcinoma[J]. J Clin Hepatol, 2020, 36( 7): 1482- 1488. DOI: 10.3969/j.issn.1001-5256.2020.07.008. 陆荫英, 赵海涛, 程家敏, 等. 肝胆肿瘤分子诊断临床应用专家共识[J]. 临床肝胆病杂志, 2020, 36( 7): 1482- 1488. DOI: 10.3969/j.issn.1001-5256.2020.07.008.
[11]	ZHANG Y, ZUO C, LIU L, et al. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer[J]. J Hepatol, 2021, 75( 5): 1128- 1141. DOI: 10.1016/j.jhep.2021.06.023.
[12]	TIWARI PK. Epigenetic biomarkers in gallbladder cancer[J]. Trends Cancer, 2020, 6( 7): 540- 543. DOI: 10.1016/j.trecan.2020.03.003.
[13]	TEKCHAM DS, POOJARY SS, BHUNIA S, et al. Epigenetic regulation of APC in the molecular pathogenesis of gallbladder cancer[J]. Indian J Med Res, 2016, 143( Supplement): S82- S90. DOI: 10.4103/0971-5916.191792.
[14]	WANG YF, FENG FL, ZHAO XH, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer[J]. World J Gastroenterol, 2014, 20( 14): 4085- 4092. DOI: 10.3748/wjg.v20.i14.4085.
[15]	KONG WH, ZHANG L, AN R, et al. Diagnostic value of serum D-dimer for detection of gallbladder carcinoma[J]. Cancer Manag Res, 2021, 13: 2549- 2556. DOI: 10.2147/CMAR.S272116.
[16]	CHEN XF, WANG DQ, LIU J, et al. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes[J]. J Immunother Cancer, 2021, 9( 11): e003214. DOI: 10.1136/jitc-2021-003214.
[17]	XUE XY, LIU YX, WANG C, et al. Identification of exosomal miRNAs as diagnostic biomarkers for cholangiocarcinoma and gallbladder carcinoma[J]. Signal Transduct Target Ther, 2020, 5( 1): 77. DOI: 10.1038/s41392-020-0162-6.
[18]	ZHANG XZ, LI L, ZHANG M, et al. Intelligent recognition of CTCs from gallbladder cancer by ultrasensitive electrochemical cytosensor and diagnosis of chemotherapeutic resistance[J]. Biosens Bioelectron, 2023, 228: 115183. DOI: 10.1016/j.bios.2023.115183.
[19]	YANG ZY, LIU SL, CAI C, et al. Interpretation of the Gallbladder reporting and data system(GB‑RADS) for risk stratification of gallbladder wall thickening on ultrasonography: an international expert consensus[J]. Chin J Dig Surg, 2022, 21( 7): 852- 857. DOI: 10.3760/cma.j.cn115610-20220505-00252. 杨自逸, 刘诗蕾, 蔡晨, 等.《胆囊壁增厚超声检查评估分级系统国际专家共识》解读[J]. 中华消化外科杂志, 2022, 21( 7): 852- 857. DOI: 10.3760/cma.j.cn115610-20220505-00252.
[20]	BO XB, CHEN EB, WANG J, et al. Diagnostic accuracy of imaging modalities in differentiating xanthogranulomatous cholecystitis from gallbladder cancer[J]. Ann Transl Med, 2019, 7( 22): 627. DOI: 10.21037/atm.2019.11.35.
[21]	BASU SM, GUPTA M, RANA P, et al. RadFormer: Transformers with global-local attention for interpretable and accurate Gallbladder Cancer detection[J]. Med Image Anal, 2023, 83: 102676. DOI: 10.1016/j.media.2022.102676.
[22]	CHOI SY, KIM JH, PARK HJ, et al. Preoperative CT findings for prediction of resectability in patients with gallbladder cancer[J]. Eur Radiol, 2019, 29( 12): 6458- 6468. DOI: 10.1007/s00330-019-06323-4.
[23]	TAN CH, LIM KS. MRI of gallbladder cancer[J]. Diagn Interv Radiol, 2013, 19( 4): 312- 319. DOI: 10.5152/dir.2013.044.
[24]	SASAKI F, NAKAMOTO R, TOKUNAGA K, et al. 18F-FDG PET/CT findings of G-CSF-producing gallbladder cancer[J]. Clin Nucl Med, 2022, 47( 4): e368- e369. DOI: 10.1097/RLU.0000000000004054.
[25]	JIA X, LI XR, JIA B, et al. The role of[^99mTc]Tc-HFAPi SPECT/CT in patients with malignancies of digestive system: First clinical experience[J]. Eur J Nucl Med Mol Imaging, 2023, 50( 4): 1228- 1239. DOI: 10.1007/s00259-022-06068-1.
[26]	SHINDOH J, DE ARETXABALA X, ALOIA TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: An international multicenter study[J]. Ann Surg, 2015, 261( 4): 733- 739. DOI: 10.1097/SLA.0000000000000728.
[27]	GHOLAMI S, COLBY S, HOROWITZ DP, et al. Adjuvant chemoradiation in patients with lymph node-positive biliary tract cancers: Secondary analysis of a single-arm clinical trial(SWOG 0809)[J]. Ann Surg Oncol, 2023, 30( 3): 1354- 1363. DOI: 10.1245/s10434-022-12863-9.
[28]	JULKA PK, PURI TR, RATH GK. A phase Ⅱ study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2006, 5( 1): 110- 114.
[29]	BRIDGEWATER J, FLETCHER P, PALMER DH, et al. Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP study[J]. J Clin Oncol, 2022, 40( 18): 2048- 2057. DOI: 10.1200/JCO.21.02568.
[30]	PRIMROSE JN, FOX RP, PALMER DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): A randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20( 5): 663- 673. DOI: 10.1016/S1470-2045(18)30915-X.
[31]	VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362( 14): 1273- 1281. DOI: 10.1056/NEJMoa0908721.
[32]	MORIZANE C, OKUSAKA T, MIZUSAWA J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT(JCOG1113) randomized phase Ⅲ clinical trial[J]. Ann Oncol, 2019, 30( 12): 1950- 1958. DOI: 10.1093/annonc/mdz402.
[33]	SHROFF RT, JAVLE MM, XIAO LC, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial[J]. JAMA Oncol, 2019, 5( 6): 824- 830. DOI: 10.1001/jamaoncol.2019.0270.
[34]	CUI XY, LI XC, CUI JJ, et al. Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen[J]. Hepatobiliary Surg Nutr, 2021, 10( 4): 498- 506. DOI: 10.21037/hbsn-20-846.
[35]	IOKA T, KANAI M, KOBAYASHI S, et al. Randomized phase Ⅲ study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer(KHBO1401-MITSUBA)[J]. J Hepatobiliary Pancreat Sci, 2023, 30( 1): 102- 110. DOI: 10.1002/jhbp.1219.
[36]	ZHANG YJ, ZUO CM, LIU LG, et al. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer[J]. J Hepatol, 2021, 75( 5): 1128- 1141. DOI: 10.1016/j.jhep.2021.06.023.
[37]	JAVLE M, CHURI C, KANG HC, et al. HER2/neu-directed therapy for biliary tract cancer[J]. J Hematol Oncol, 2015, 8: 58. DOI: 10.1186/s13045-015-0155-z.
[38]	JAVLE M, BORAD MJ, AZAD NS, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer(MyPathway): A multicentre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2021, 22( 9): 1290- 1300. DOI: 10.1016/S1470-2045(21)00336-3.
[39]	LIN JZ, LONG JY, WAN XS, et al. Classification of gallbladder cancer by assessment of CD8⁺ TIL and PD-L1 expression[J]. BMC Cancer, 2018, 18( 1): 766. DOI: 10.1186/s12885-018-4651-8.
[40]	OTT PA, BANG YJ, PIHA-PAUL SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028[J]. J Clin Oncol, 2019, 37( 4): 318- 327. DOI: 10.1200/JCO.2018.78.2276.
[41]	KASSAB J, SABA L, GEBRAEL G, et al. Update on immunotherapy in the management of gallbladder cancer[J]. Immunotherapy, 2023, 15( 1): 35- 42. DOI: 10.2217/imt-2022-0191.
[42]	FENG KC, LIU Y, GUO YL, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers[J]. Protein Cell, 2018, 9( 10): 838- 847. DOI: 10.1007/s13238-017-0440-4.
[43]	FENG KC, GUO YL, LIU Y, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma[J]. J Hematol Oncol, 2017, 10( 1): 4. DOI: 10.1186/s13045-016-0378-7.
[44]	HACK SP, VERRET W, MULLA S, et al. IMbrave 151: A randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer[J]. Ther Adv Med Oncol, 2021, 13: 17588359211036544. DOI: 10.1177/17588359211036544.
[45]	LEE CK, CHON HJ, CHEON J, et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: A multi-institutional phase 2 trial of the Korean Cancer Study Group(KCSG-HB19-14)[J]. Lancet Gastroenterol Hepatol, 2023, 8( 1): 56- 65. DOI: 10.1016/S2468-1253(22)00335-1.
[46]	SHI GM, HUANG XY, WU D, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study[J]. Signal Transduct Target Ther, 2023, 8( 1): 106. DOI: 10.1038/s41392-023-01317-7.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (467) PDF downloads(143)

Advances in the diagnosis and treatment of gallbladder carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.11.032

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Advances in the diagnosis and treatment of gallbladder carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.11.032

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content